Horizon Technology Finance

Horizon targets venture-backed companies in technology, life sciences, healthcare information and services, and sustainability that have typically raised at least $15 million in institutional venture capital. The firm focuses on expansion-stage businesses that are already generating revenue, which distinguishes its credit quality from lenders that underwrite pre-revenue startups. Borrowers often include enterprise software, diagnostics, and industrial biotechnology companies.

Horizon is organized as a publicly traded business development company that trades on the Nasdaq under the ticker HRZN. As a BDC, it must distribute at least 90 percent of its taxable income to shareholders and is subject to regulatory leverage limits. The company is externally managed, meaning the investment adviser — Horizon Technology Finance Management LLC — earns management and incentive fees from the BDC's operations.

Investment decisions are made by the leadership team of Horizon Technology Finance Management LLC, the external adviser. Gerald A. Michaud serves as President and Robert D. Pomeroy Jr. as CEO. The adviser's investment committee reviews and approves all credit decisions, drawing on the underwriting team's due diligence on prospective portfolio companies and their venture capital sponsors.

Horizon primarily originates senior secured term loans but typically receives warrant coverage or equity co-investment rights alongside its debt. This structure provides current income from loan interest payments and potential upside from the borrower's growth. The warrants and equity positions are held on the balance sheet and realized upon acquisition, IPO, or secondary sale of the underlying portfolio company.

Deal flow comes through relationships with venture capital firms that introduce portfolio companies seeking non-dilutive growth capital. Horizon does not typically source directly from cold corporate outreach. The firm's origination team works with VC sponsors across the United States, and a borrower's existing institutional backing is a key underwriting criterion.

Horizon co-invests through warrant positions and occasional direct equity sidecars in the same portfolio companies to which it lends. The firm launched a separate joint venture in September 2022 with a large institutional investor to pool capital for additional venture lending, expanding its co-investment footprint beyond the core BDC balance sheet.

Horizon does not publicly maintain an explicit exclusion list, but its revenue-stage focus effectively screens out pre-revenue biotechnology and pre-product software companies. The firm also does not lend to companies outside of technology, life sciences, healthcare information, and sustainability, which excludes sectors like traditional manufacturing, retail, and hospitality.